Chronomics

About:

Tech-bio company, providing access to a ‘bio-infrastructure’ to simplify and speed-up the use of biomarkers to improve everyday decisions.

Website: https://www.chronomics.com

Twitter/X: chronomentary

Top Investors: SOSV, Anthemis, RebelBio

Description:

Chronomics is a tech-bio company on a mission to make biology accessible and actionable to everyone. The world is at the dawn of a ‘bio-revolution’ - with science set to transform our lives in the coming decades. And yet today, accessing biological information - and making it actionable - is complex, costly and cumbersome. The revolution needs an engine - and we are building it. We design and deploy ‘bio-infrastructure’ across more than a dozen verticals to simplify, speed-up and scale the use of biomarkers to improve everyday decisions. From tele-health to travel; sleep to skincare; multivitamins to managing menopause - and many others - we partner with the world’s largest and most impactful organizations, using science to transform how they diagnose, personalize and evaluate their offerings. Co-located between the US and Europe, we’re a team that spans science, technology, supply chain, operations, commercial - and we’re growing. Rapidly.

Total Funding Amount:

1.12M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2017-12-20

Contact Email:

solutions(AT)chronomics.com

Founders:

Charles Ball, Daniel Elías Martín Herranz, Robin Thompson, Toby Call, Tom Stubbs

Number of Employees:

11-50

Last Funding Date:

2019-01-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai